Heart Failure
Conditions
Brief summary
Cardiological examination constitute one of the major directions in nuclear medicine for detection of myocardial ischemia in patients suspected of coronary disease. In Caen, they constitute 20% of the activity of nuclear medicine. Systolic heart failure (HF) ischemic or nonischemic origin represents a new area of activity of the nuclear cardiology. This is HF stratification study based on cardiac adrenergic function after injection of a tracer: I-123-MIBG. The team Caen nuclear cardiology is one of two teams recognized internationally in the field of evaluating the cardiac sympathetic innervation in cardiomyopathies. Numerous publications from 1992 to the present day have reported encouraging results for the daily use of this tracer in the evaluation of patients with LV dysfunction IC. Recently, interest in using the MIBG has been shown as a prognostic marker of HF in a prospective study of 961 patients. Typically, the camera used was an Anger camera with collimating Nai standard called parallel holes. The main objective is to validate the measurements of cardiac adrenergic function evaluated by cardiopulmonary mediastinal reports and sympathetic innervation scores VG after injection of I-123-MIBG in 80 patients with heart failure.
Interventions
DRUGI-123-MIBG
DEVICECZT Camera (D-SPECT)
DEVICEAnger Camera
Sponsors
University Hospital, Caen
Study design
Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age above 18 years (except major patients under guardianship) * patient who signed the consent form * written and spoken French * Beneficiaries of the social security system * Stable heart failure with LV dysfunction (\<45%) of ischemic or nonischemic origin
Exclusion criteria
* Patients with a recent history (\<21 days) acute coronary failure (myocardial infarction, unstable angina) * Patients with severe extra-cardiac disease may interfere with treatment decisions (cancer, severe hepatic or renal impairment) * Major patients under guardianship * Pregnant or lactating women * Women in age and condition of childbearing * Patients unable to understand the purpose of the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| SRSI (summed rest score innervation) | 4 hours after I-123-MIBG perfusion | with CZT camera and Anger camera |
| SRS (summed rest score) | 4 hours after I-123-MIBG perfusion | with CZT camera and Anger camera |
Countries
France
Outcome results
None listed